B
ASMB icon

Bailard’s Assembly Biosciences ASMB Stock Holding History

Bailard’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,083
Closed -$1.99M – 628
2020
Q3 		$1.99M Sell
10,083
-1,667
-14% -$420K 0.1% 150
2020
Q2 		$3.29M Sell
11,750
-6,125
-34% -$1.43M 0.18% 109
2020
Q1 		$3.18M Buy
17,875
+7,125
+66% +$1.53M 0.23% 90
2019
Q4 		$2.64M Buy
+10,750
New +$1.98M 0.15% 126

Other funds holding ASMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Bailard's ASMB Position: Q4 2020 in Review

Bailard sold out of Assembly Biosciences (ASMB) in Q4 2020, closing a stake of 10,083 shares — an estimated $1.99M sold.

Bailard first reported a position in ASMB in Q4 2019 and held it in 4 quarters. The position peaked at $3.29M in Q2 2020. 109 funds tracked by Wall St. Rank hold ASMB as of Q4 2020.

  • Bailard reported no remaining Assembly Biosciences position as of Q4 2020 after selling out during the quarter.
  • Bailard sold 10,083 Assembly Biosciences shares in Q4 2020, an estimated $1.99M.
  • Bailard first reported a position in Assembly Biosciences in Q4 2019 and held it in 4 quarters.
  • Bailard's Assembly Biosciences position peaked at $3.29M in Q2 2020.
  • 109 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2020.

Based on Bailard's 13F filing for Q4 2020, filed 3 Feb 2021.